MedTrace Logo

Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum

NCT04761393 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2024-11-20

No results posted yet for this study

Summary

The hypothesis is that in patients with emphysema, a high MMP12 sputum and/or blood level correlates with airspace enlargement and with increased sputum Th2 immune biomarkers.

Conditions

  • Emphysema

Interventions

PROCEDURE

Hyperpolarized 129Xe (Xenon) diffusion-weighted MRI

Participants will inhale a one litre gas mixture containing hyperpolarized 129Xe mixed with nitrogen (N2) or helium (4He) from a one litre dose bag. Breath-hold will be up to 16 seconds

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-29
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04761393 on ClinicalTrials.gov